LNCB-74

N/A

Report date: 2025/01/13 13:24:49

Base Information

Drug NameLNCB-74
Drug Alias NameB7-H4 targeting antibody drug conjugate(LegoChem/NextCure)LNCB-74LNCB74LCB41A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-V-set domain-containing T-cell activation inhibitor 1DNA cross linking agentsDNA damage stimulants
TargetsV-set domain-containing T-cell activation inhibitor 1DNA
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNextcure IncLigaChem Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesLigaChem Biosciences IncLegochem Biosciences IncNextcure Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A